Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep

# Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep ## Overview Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep is an antiviral medication used in the treatment of chronic Hepatitis B virus (HBV) infection. It is a nucleoside analog that inhibits HBV DNA polymerase, the enzyme responsible for viral replication. ## Primary Indications Chronic Hepatitis B virus infection in adults and pediatric patients. ## Adult Dosing The typical dose is 0.5 mg orally once daily. ## Pediatric Dosing For pediatric patients aged 12 years and older and weighing at least 35 kg, the dose is 0.5 mg orally once daily. Dosing for younger children or those with lower weight is not established and may depend on local protocols. ## Dose Adjustments **Renal Impairment:** * **CrCl > 50 mL/min:** No dose adjustment needed. * **CrCl 30-50 mL/min:** 0.5 mg every 48 hours. * **CrCl 10-29 mL/min:** 0.5 mg every 72 hours. * **CrCl < 10 mL/min or Hemodialysis/Continuous Ambulatory Peritoneal Dialysis (CAPD):** 0.5 mg every 7 days or after each dialysis session. **Hepatic Impairment:** No dose adjustment is generally required. However, caution is advised in patients with severe hepatic impairment. ## Contraindications * Hypersensitivity to the active ingredient or any excipients. * Patients with severe renal impairment not adequately managed with dose adjustments. ## Adverse Effects Common adverse effects include headache, nausea, abdominal pain, fatigue, dizziness, and insomnia. Serious adverse effects may include lactic acidosis, severe hepatomegaly with steatosis, and development of resistance. ## Key Drug Interactions * **Didanosine:** Concurrent use is contraindicated due to an increased risk of lactic acidosis and pancreatitis. * **Other nephrotoxic drugs (e.g., aminoglycosides, NSAIDs, certain diuretics):** Use with caution as this may increase the risk of renal adverse effects. ## Monitoring * Regular monitoring of HBV DNA levels to assess treatment efficacy. * Liver function tests (ALT, AST, bilirubin) to monitor for hepatotoxicity. * Renal function (serum creatinine, CrCl) to guide dose adjustments. * Monitor for signs and symptoms of lactic acidosis or severe hepatomegaly. ## Clinical Pearls * Tab%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep should be taken on an empty stomach, at least 2 hours before or 2 hours after a meal. * Treatment should not be stopped abruptly due to the risk of HBV flare. * Patients should be counseled on the importance of adherence and the potential for drug resistance. * Combination therapy with other antivirals is generally not recommended unless resistance develops. *** *Disclaimer: This information is intended for educational purposes only and does not substitute for professional medical advice. Always consult with a qualified healthcare provider or refer to the most current prescribing information for definitive guidance.*